Daisuke Tsutsumi
Overview
Explore the profile of Daisuke Tsutsumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uchiike A, Kono H, Miura K, Hayama T, Tsutsumi D, Tsuboi S, et al.
J Pharm Health Care Sci
. 2023 Jul;
9(1):24.
PMID: 37525281
Background: Olanzapine treatment prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). However, its role in the secondary prevention of breakthrough CINV in real-world cancer care...
2.
Tsuboi S, Hayama T, Miura K, Uchiike A, Tsutsumi D, Yamauchi T, et al.
J Pharm Health Care Sci
. 2023 Apr;
9(1):16.
PMID: 37060091
No abstract available.
3.
Tsuboi S, Hayama T, Miura K, Uchiike A, Tsutsumi D, Yamauchi T, et al.
J Pharm Health Care Sci
. 2023 Jan;
9(1):2.
PMID: 36627672
Background: Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant...
4.
Tsutsumi D, Hayama T, Miura K, Uchiike A, Tsuboi S, Otsuka S, et al.
Int J Clin Pharm
. 2021 Dec;
44(2):366-373.
PMID: 34894347
Background Infusion-related reactions (IRRs) during rituximab administration are occasionally severe and remain problematic in oncology practice. Aim To establish a safer, risk-stratified rituximab protocol for patients with B-cell lymphoma. Method...
5.
Ooba N, Sente A, Abe M, Watanabe F, Tsutsumi D, Nakamura K, et al.
Biol Pharm Bull
. 2020 Mar;
43(5):913-916.
PMID: 32132314
Guidelines for cardiovascular drug therapy recommend monitoring serum digoxin concentration (SDC) in patients receiving digoxin treatment, especially those with renal dysfunction and hypokalemia. However, only a few studies have reported...
6.
Kiyota T, Shiota S, Hamanaka R, Tsutsumi D, Takakura T, Miyazaki E
Case Rep Med
. 2019 Feb;
2019:4917856.
PMID: 30809261
An 83-year-old man under warfarin therapy presented for assessment of prolonged prothrombin time and cough. High-resolution computed tomography findings of the chest showed diffuse alveolar hemorrhage. His international normalized ratio...
7.
Ooba N, Tsutsumi D, Kobayashi N, Hidaka S, Hayashi H, Obara T, et al.
Ther Drug Monit
. 2018 Feb;
40(2):252-256.
PMID: 29420333
Background: Therapeutic drug monitoring (TDM) for lithium is recommended in guidelines; however, the prevalence of TDM for lithium is seldom reported. We have therefore investigated the prevalence of TDM for...
8.
Hayama T, Miura K, Uchiike A, Nakagawa M, Tsutsumi D, Sakagami M, et al.
Int J Clin Pharm
. 2017 Feb;
39(2):380-385.
PMID: 28144804
Background Infusion-related reactions (IRRs) are a major adverse event of rituximab. Objective To develop a prediction model for IRRs to rituximab among patients with B cell non- Hodgkin's lymphomas (B-NHL)....
9.
Karahashi M, Hirata-Hanta Y, Kawabata K, Tsutsumi D, Kametani M, Takamatsu N, et al.
Lipids
. 2016 Jul;
51(8):955-71.
PMID: 27372943
The Goto-Kakizaki (GK) rat is widely used as an animal model for spontaneous-onset type 2 diabetes without obesity; nevertheless, little information is available on the metabolism of fatty acids and...